Sprycel (dasatinib) — Medica
Philadelphia chromosome-positive chronic myeloid leukemia (CML)
Initial criteria
- Patient has Philadelphia chromosome-positive chronic myeloid leukemia.
Reauthorization criteria
- Patient continues to meet initial criteria.
Approval duration
1 year